Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATA-200 gene therapy in LGMDR5
NCT05973630Phase 1Active, not recruiting
- Sponsor
- Atamyo Therapeutics
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GNT0007 in limb-girdle muscular dystrophy type 2C (LGMD2C), sponsored by Atamyo Therapeutics. Primary endpoints: Adverse Events at 6 months, Treatment-Emergent Adverse Events at 6 months and 1 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
GNT0007
03
Conditions
limb-girdle muscular dystrophy type 2C (LGMD2C)
Beyond the preview
Go deeper on NCT05973630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973630.